Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note released on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their price objective on shares of Minerva Neurosciences from $11.00 to $7.00 and set a neutral rating on the stock in a research note on Thursday, May 2nd.

Minerva Neurosciences Stock Down 2.7 %

NASDAQ:NERV traded down $0.08 during trading hours on Tuesday, reaching $2.88. The company had a trading volume of 17,968 shares, compared to its average volume of 68,939. The firm has a market cap of $20.14 million, a price-to-earnings ratio of -0.64 and a beta of 0.15. The business’s 50-day simple moving average is $3.18 and its two-hundred day simple moving average is $3.87. Minerva Neurosciences has a twelve month low of $2.26 and a twelve month high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). As a group, equities analysts predict that Minerva Neurosciences will post -1.89 earnings per share for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.